<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366048">
  <stage>Registered</stage>
  <submitdate>26/03/2014</submitdate>
  <approvaldate>31/03/2014</approvaldate>
  <actrnumber>ACTRN12614000342617</actrnumber>
  <trial_identification>
    <studytitle>A randomised cross-over trial to compare the effects of calcium citrate, dairy products and calcium-fortified fruit juice on serum calcium concentrations in normal postmenopausal women</studytitle>
    <scientifictitle>In postmenopausal women what are the effects of calcium citrate, dairy products and calcium-fortified fruit juice on serum calcium concentrations?</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Osteoporosis</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Other diet and nutrition disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoporosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A single dose of each of the following three treatments after fasting for at least 8 hours: 0.5 g of calcium as citrate (oral tablet) after a meal containing protein and fat, 0.5 g of calcium from unfortified dairy products (milk, yoghurt and cheese) or 0.5 g of calcium from a calcium-fortified fruit juice. Each dose will be separated by at least 7 days.</interventions>
    <comparator>A single dose of 0.5 g of calcium as citrate (oral tablet) after fasting for at least 8 hours.</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in serum calcium</outcome>
      <timepoint>1, 2, 4 and 6 hours after the treatment is ingested</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in serum phosphate</outcome>
      <timepoint>1, 2, 4 and 6 hours after the treatment is ingested</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Female, postmenopausal 5 years or more (menopause defined as at least 12 months since last period in a woman aged &gt; 45 yrs with intact uterus, or serum oestradiol &lt; 100 pmol/l with FSH &gt; 50 IU/l in younger or hysterectomised woman).</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Renal impairment (serum creatinine &gt;0.15 mmol/L), chronic liver disease, untreated hypothyroidism or hyperthyroidism, concurrent major systemic illness (including malignancy), active major gastrointestinal disease, metabolic bone diseases, or serum ALP &gt;normal, primary hyperparathyroidism, current or expected use of oral glucocorticoid drugs during the trial period, current or past use of bisphosphonate therapy in the preceding 2 years, use of hormone replacement therapy within the last 12 months, use of other medication known to cause osteoporosis or interfere with bone metabolism.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics / pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>26/10/2012</anticipatedstartdate>
    <actualstartdate>26/10/2012</actualstartdate>
    <anticipatedenddate>5/05/2013</anticipatedenddate>
    <actualenddate>5/05/2013</actualenddate>
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Auckland</primarysponsorname>
    <primarysponsoraddress>Faculty of Medical and Health Sciences
University of Auckland
Private Bag 92019
Auckland 1142
New Zealand
</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Council</fundingname>
      <fundingaddress>PO Box 5541
Wellesley Street
Auckland
1141</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Calcium supplements have been associated with increased cardiovascular risk, which might be related to their acute effects on serum calcium. This study aims to compare the effects on serum calcium of 0.5 g of calcium as citrate fasting, as citrate after a protein and fat rich meal, from unfortified dairy products or from calcium-fortified juice.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Health and Disabilities Ethics Committees</ethicname>
      <ethicaddress>Ministry of Health
1 the Terrace
PO Box 5013
Wellington 6145</ethicaddress>
      <ethicapprovaldate>1/10/2012</ethicapprovaldate>
      <hrec>NTX/10/12/125</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Ian Reid</name>
      <address>Faculty of Medical and Health Sciences University of Auckland Private Bag 92019 Auckland 1142</address>
      <phone>+64 9 3737 599 ext 86259</phone>
      <fax />
      <email>i.reid@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Ian Reid</name>
      <address>Faculty of Medical and Health Sciences University of Auckland Private Bag 92019 Auckland 1142</address>
      <phone>+64 9 3737 599 ext 86259</phone>
      <fax />
      <email>i.reid@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Ian Reid</name>
      <address>Faculty of Medical and Health Sciences University of Auckland Private Bag 92019 Auckland 1142</address>
      <phone>+64 9 3737 599 ext 86259</phone>
      <fax />
      <email>i.reid@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sarah Bristow</name>
      <address>Faculty of Medical and Health Sciences University of Auckland Private Bag 92019 Auckland 1142</address>
      <phone>+64 9 923 3773</phone>
      <fax />
      <email>s.bristow@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>